Genentech, Inc.

F. Hoffmann-la Roche Ag

Ingrid Wertz

Peter Scott Dragovich

Thomas Pillow

Steven T Staben

Chudi Obioma Ndubaku

BinQing Wei

Richard Pastor

Wayne J Fairbrother

Lori Friedman

Robert Anthony Blake

Deepak Sampath

Vickie H Tsui

Nicole Blaquiere

Leanna Staben

Jack Sadowsky

Gail Lewis Phillips

Jeremy M Murray

Till Maurer

Jason Drummond

Christine Johanna Heideker

Lorna Kategaya

Lionel Rouge

Kebing Yu

Pragya Adhikari

Paola Di Lello

Kyle Edgar

Kyung Song

Timothy Wilson

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

Conjugated chemical inducers of degradation and methods of use

The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

PROTAC antibody conjugates and methods of use

The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.

Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor

2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

USP7 inhibitor compounds and methods of use

Growing community of inventors

South San Francisco, CA, United States of America

Ingrid Wertz